BIO-PATH HOLDINGS, INC. 8-K

What Happened
BIO-PATH Holdings, Inc. (BPTH) filed an 8‑K reporting several material corporate actions and strategic moves between April and July 2026. On July 14, 2026 the board approved a new class of Series B Preferred stock (5,000,000 authorized), each share convertible into 1,000 common shares, voting as converted, no dividends and no liquidation preference above $0.01 par. Earlier, under a qualified Tier 1 Regulation A offering the company sold common shares on April 30 (466,100 shares, $13,983 net) and May 13 (489,200 shares, $14,676 net) and noted it could raise an additional ~$571,341 under that offering. The filing also discloses a planned strategic turnaround effort that includes restarting drug trials, licensing or selling IP, pursuing crypto/blockchain financing, and pursuing outside capital.

Key Details

• Series B Preferred: 5,000,000 authorized; convertible into 1,000 common shares each; votes on an as‑converted basis; no dividends; par value $0.01. Certificate to be filed with Wyoming Secretary of State (stamped copy expected in early August).
• Regulation A sales: April 30, 2026 — 466,100 common shares for $13,983 net; May 13, 2026 — 489,200 common shares for $14,676 net; ~ $571,341 capacity remains under the offering.
• Clinical trial update: UT MD Anderson agreed June 5, 2026 to restart Phase 2 AML trials provided BIO-PATH brings trial accounts current — $292,264.21 owed for BP1001-201-AML and $63,286.55 for BP1002-201-AML (total ~$355,550.76).
• Corporate/crypto moves: On June 26, 2026 BIO-PATH opened a business account with Coinbase and plans to allocate up to 50% of capital raised to crypto opportunities. On July 6 the company issued Series B and Series M preferred in a transaction valuing the consideration at $670,260 that made Himalaya Technologies, Inc. a majority‑owned subsidiary; it also issued Series B shares to the CEO valued at $11,069. On July 3 BIO-PATH engaged Farrington Capital Group (60‑day exclusivity) to seek strategic investors, buyers, JV partners or licensors. On July 14 BIO-PATH added Richard Fetyko (altFINS) to its advisory board and signed an LOI with altFINS for cross‑investment and potential share issuances/options.

Why It Matters

• Potential dilution: The Series B structure (1 Series B = 1,000 common shares on conversion) and large authorized amount could materially increase outstanding common‑share equivalents if converted or issued, affecting current shareholders.
• Mixed strategic direction: Management is pursuing multiple paths — restarting clinical trials (which requires curing arrears), seeking partners or buyers for its biotech IP, and expanding into crypto and digital asset treasury management. Investors should note these are strategic options, not guarantees of success.
• Small immediate capital but active fundraising: Recent Reg A sales raised modest net proceeds; the company still has capacity under the offering but will likely need larger financing or deals to fund trial restarts and other initiatives.
• Transactions and advisory arrangements: The acquisition of Himalaya Technologies (crypto/social/trading platform), engagement of Farrington Capital Group, and LOI with altFINS indicate a push toward crypto and strategic partnerships; these moves shift BIO-PATH’s profile beyond pure biotech and could change risk/reward dynamics.

Keywords: Regulation A, Series B preferred, convertible shares, Phase 2 trials, MD Anderson, Coinbase, crypto treasury, Farrington Capital, altFINS, dilution, fundraising.